TY - JOUR
T1 - cdc25A and the splicing variant cdc25B2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas
AU - Hernandez, S
AU - Hernandez, L
AU - Bea, S
AU - Pinyol, M
AU - Nayach, Iracema
AU - Bellosillo, B
AU - Nadal, A
AU - Ferrer, A
AU - Fernandez, PL
AU - Montserrat, E
AU - Cardesa, A
AU - Campo, E
PY - 2000/3/20
Y1 - 2000/3/20
N2 - cdc25 is a Family of phosphatases that activate the cyclin-dependent kinases at different points of the cell cycle. cdc25A and -B, but not -C, have been shown to have oncogenic potential, Three different splicing variants of the cdc25B gene, cdc25B1, -B2 and -B3, have also been identified. Experimental studies suggest that cdc25B2 may be more active in vivo than cdc25B3 and -B1, but the relative expression of these splicing variants in human tumors is not. known. In this study, we have analyzed the expression of cdc25A, -B1, -B2, -B3 and -C mRNA in 9 non-neoplastic lymphoid samples, 89 non-Hodgkin's lymphomas and 9 hematological cancer cell lines by semi-quantitative RT-PCR, cdc25A, -B and -C protein expression was examined by Western blot. Normal peripheral blood lymphocytes and reactive tissues expressed cdc25B1 and -B3 mRNA and very low or undetectable levels of cdc25A, -B2 and -C, High levels of cdc25A and cdc25B2 were found in 35% and 39% of the tumors, respectively, and they were more frequently observed in aggressive than in indolent lymphomas, cdc25B1 and -B3 splice variants were detected in virtually all tumors, and no significant differences were found between high- and low-grade lymphomas, cdc25A and -B protein expression was also higher in aggressive than in indolent lymphomas, cdc25C expression was relatively low in virtually all cases. In conclusion, these findings suggest that cdc25A and -B2, but not cdc25B1, -B3 and -C, are over-expressed in a relatively large number of malignant lymphomas and may participate in the pathogenesis of aggressive variants. (C) 2000 Wiley-Liss, Inc.
AB - cdc25 is a Family of phosphatases that activate the cyclin-dependent kinases at different points of the cell cycle. cdc25A and -B, but not -C, have been shown to have oncogenic potential, Three different splicing variants of the cdc25B gene, cdc25B1, -B2 and -B3, have also been identified. Experimental studies suggest that cdc25B2 may be more active in vivo than cdc25B3 and -B1, but the relative expression of these splicing variants in human tumors is not. known. In this study, we have analyzed the expression of cdc25A, -B1, -B2, -B3 and -C mRNA in 9 non-neoplastic lymphoid samples, 89 non-Hodgkin's lymphomas and 9 hematological cancer cell lines by semi-quantitative RT-PCR, cdc25A, -B and -C protein expression was examined by Western blot. Normal peripheral blood lymphocytes and reactive tissues expressed cdc25B1 and -B3 mRNA and very low or undetectable levels of cdc25A, -B2 and -C, High levels of cdc25A and cdc25B2 were found in 35% and 39% of the tumors, respectively, and they were more frequently observed in aggressive than in indolent lymphomas, cdc25B1 and -B3 splice variants were detected in virtually all tumors, and no significant differences were found between high- and low-grade lymphomas, cdc25A and -B protein expression was also higher in aggressive than in indolent lymphomas, cdc25C expression was relatively low in virtually all cases. In conclusion, these findings suggest that cdc25A and -B2, but not cdc25B1, -B3 and -C, are over-expressed in a relatively large number of malignant lymphomas and may participate in the pathogenesis of aggressive variants. (C) 2000 Wiley-Liss, Inc.
KW - CELL-CYCLE
KW - ACTIVATION
KW - PHOSPHATASE
KW - DEPHOSPHORYLATION
KW - PHOSPHORYLATION
KW - OVEREXPRESSION
KW - P34(CDC2)
KW - HOMOLOG
KW - PROTEIN
KW - KINASE
U2 - 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.3.CO;2-I
DO - 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.3.CO;2-I
M3 - Article
VL - 89
SP - 148
EP - 152
IS - 2
ER -